These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 21828138)

  • 21. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
    Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
    Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models.
    Ke H; Zhang F; Wang J; Xiong L; An X; Tu X; Chen C; Wang Y; Mao B; Guo S; Ju C; He X; Sun R; Zhang L; O'Connor OA; Li QX
    Sci Rep; 2023 Apr; 13(1):5419. PubMed ID: 37012357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 24. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
    Willingham SB; Volkmer JP; Gentles AJ; Sahoo D; Dalerba P; Mitra SS; Wang J; Contreras-Trujillo H; Martin R; Cohen JD; Lovelace P; Scheeren FA; Chao MP; Weiskopf K; Tang C; Volkmer AK; Naik TJ; Storm TA; Mosley AR; Edris B; Schmid SM; Sun CK; Chua MS; Murillo O; Rajendran P; Cha AC; Chin RK; Kim D; Adorno M; Raveh T; Tseng D; Jaiswal S; Enger PØ; Steinberg GK; Li G; So SK; Majeti R; Harsh GR; van de Rijn M; Teng NN; Sunwoo JB; Alizadeh AA; Clarke MF; Weissman IL
    Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6662-7. PubMed ID: 22451913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.
    Edris B; Weiskopf K; Volkmer AK; Volkmer JP; Willingham SB; Contreras-Trujillo H; Liu J; Majeti R; West RB; Fletcher JA; Beck AH; Weissman IL; van de Rijn M
    Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6656-61. PubMed ID: 22451919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.
    Chao MP; Alizadeh AA; Tang C; Jan M; Weissman-Tsukamoto R; Zhao F; Park CY; Weissman IL; Majeti R
    Cancer Res; 2011 Feb; 71(4):1374-84. PubMed ID: 21177380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience.
    Folkes AS; Feng M; Zain JM; Abdulla F; Rosen ST; Querfeld C
    Curr Opin Oncol; 2018 Sep; 30(5):332-337. PubMed ID: 29994903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of CD47 in Hematological Malignancies.
    Eladl E; Tremblay-LeMay R; Rastgoo N; Musani R; Chen W; Liu A; Chang H
    J Hematol Oncol; 2020 Jul; 13(1):96. PubMed ID: 32677994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential.
    Ma L; Zhu M; Gai J; Li G; Chang Q; Qiao P; Cao L; Chen W; Zhang S; Wan Y
    J Nanobiotechnology; 2020 Jan; 18(1):12. PubMed ID: 31931812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma.
    Lo J; Lau EY; So FT; Lu P; Chan VS; Cheung VC; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
    Liver Int; 2016 May; 36(5):737-45. PubMed ID: 26351778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
    Ring NG; Herndler-Brandstetter D; Weiskopf K; Shan L; Volkmer JP; George BM; Lietzenmayer M; McKenna KM; Naik TJ; McCarty A; Zheng Y; Ring AM; Flavell RA; Weissman IL
    Proc Natl Acad Sci U S A; 2017 Dec; 114(49):E10578-E10585. PubMed ID: 29158380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durable antitumor responses to CD47 blockade require adaptive immune stimulation.
    Sockolosky JT; Dougan M; Ingram JR; Ho CC; Kauke MJ; Almo SC; Ploegh HL; Garcia KC
    Proc Natl Acad Sci U S A; 2016 May; 113(19):E2646-54. PubMed ID: 27091975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.
    Hatterer E; Chauchet X; Richard F; Barba L; Moine V; Chatel L; Broyer L; Pontini G; Bautzova T; Juan F; Calloud S; Bosson N; Charreton M; Masternak K; Buatois V; Shang L
    MAbs; 2020; 12(1):1739408. PubMed ID: 32191151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro.
    Zhang C; Cui GH; Liu F; Wu QL; Chen Y
    Acta Pharmacol Sin; 2006 Nov; 27(11):1438-46. PubMed ID: 17049119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
    Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
    Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
    [No Abstract]   [Full Text] [Related]  

  • 38. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
    Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
    Front Immunol; 2020; 11():18. PubMed ID: 32082311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
    Sim J; Sockolosky JT; Sangalang E; Izquierdo S; Pedersen D; Harriman W; Wibowo AS; Carter J; Madan A; Doyle L; Harrabi O; Kauder SE; Chen A; Kuo TC; Wan H; Pons J
    MAbs; 2019; 11(6):1036-1052. PubMed ID: 31257988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response.
    Tseng D; Volkmer JP; Willingham SB; Contreras-Trujillo H; Fathman JW; Fernhoff NB; Seita J; Inlay MA; Weiskopf K; Miyanishi M; Weissman IL
    Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11103-8. PubMed ID: 23690610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.